BLCOBausch + Lomb Corp.
BLCO
Bausch + Lomb Corp.522
Mkt Cap
$5.68BVolume
264,078.0052W High
$18.9252W Low
$11.22PE Ratio
-25.76BLCO Fundamentals
Price
$15.92Prev Close
$16.15Open
$16.1650D MA
$16.14Beta
1.17Avg. Volume
416,197.58EPS (Annual)
-$1.02P/B
0.89Rev/Employee
$392,384.61$10,971.61
Bausch + Lomb to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that Chairman and CEO Brent Saunders and Chief Medical Officer and Head of Research and Development Yehia Hashad, MD, will participate in a fireside...
Bausch + Lomb Announces 2026 Annual Meeting of Shareholder Results
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the election of the 10 directors nominated at its 2026 annual meeting of shareholders (the Annual Meeting) held on May 20, 2026. The detailed...
Bausch + Lomb Launches PreserVision AREDS3 Eye Vitamins in the United States
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the U.S. launch of PreserVision AREDS3 eye vitamins, which combine the clinically proven AREDS2 nutrients recommended by the NEI to help reduce the...
Bausch + Lomb Launches Bi-Blade+ Dual-Port Vitrectomy Cutter in Europe
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the European launch of the Bi-Blade+ advanced...
Bausch + Lomb Announces Second R&D Teach-in Webinar
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced the second event in its R&D Teach-in webinar...
Bausch + Lomb (NYSE:BLCO) Issues Earnings Results
Bausch + Lomb (NYSE:BLCO - Get Free Report) released its earnings results on Wednesday. The company reported $0.08 EPS for the quarter, beating the consensus estimate of $0.06 by $0.02. Bausch + Lomb had a negative net margin of 7.06% and a positive return on equity of 2.77%. The company had...
AI could take 'years' off the drug development process, says Bausch + Lomb CEO Brent Saunders
AI could take 'years' off the drug development process, says Bausch + Lomb CEO Brent Saunders...
Bausch + Lomb (BLCO) Q1 2026 Earnings Transcript
@media (max-width: 768px) {
.image-container {
width: 100% !important;
float: none !important;
margin: 0 0 1rem 0 !important;
}
}
Image source: The Mo...
Bausch + Lomb to Feature More Than 40 Scientific Studies at the 2026 Association for Research in Vision and Ophthalmology Annual Meeting
Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced that it will deliver more than 40 scientific...
Bausch Health Cos Q1 Earnings Call Highlights
Bausch Health Cos (NYSE:BHC) opened 2026 with what executives described as a strong performance, driven primarily by Salix and Solta Medical, while reaffirming full-year guidance for the company...
<
1
2
...
>
Compact View
Not available
Not available